Paul Tudor Jones's XENE Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 495,591 shares of Xenon Pharmaceuticals Inc. (XENE) worth $28.82 M, representing 0.05% of the portfolio. First purchased in 2022-Q2, this medium-term investment has been held for 13 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in XENE, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 241,589 shares. Largest reduction occurred in Q2 2023, reducing 29,908 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Xenon Pharmaceuticals (XENE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Xenon Pharmaceuticals (XENE) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +241,589 | Add 95.11% | 495,591 | $58.15 |
| Q4 2025 | +177,178 | Add 230.63% | 254,002 | $44.82 |
| Q3 2025 | +76,824 | New Buy | 76,824 | $40.15 |
| Q1 2025 | -8,671 | Sold Out | 0 | $0.00 |
| Q4 2024 | -28,016 | Reduce 76.36% | 8,671 | $39.20 |
| Q3 2024 | +11,455 | Add 45.40% | 36,687 | $39.37 |
| Q2 2024 | +75 | Add 0.30% | 25,232 | $38.99 |
| Q1 2024 | -18,064 | Reduce 41.79% | 25,157 | $43.05 |
| Q4 2023 | +43,221 | New Buy | 43,221 | $46.06 |
| Q2 2023 | -29,908 | Sold Out | 0 | $0.00 |
| Q1 2023 | +29,908 | New Buy | 29,908 | $0.04 |
| Q3 2022 | -20,336 | Sold Out | 0 | $0.00 |
| Q2 2022 | +20,336 | New Buy | 20,336 | $30.44 |
Paul Tudor Jones's Xenon Pharmaceuticals Investment FAQs
Paul Tudor Jones first purchased Xenon Pharmaceuticals Inc. (XENE) in Q2 2022, acquiring 20,336 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Xenon Pharmaceuticals Inc. (XENE) for 13 quarters since Q2 2022.
Paul Tudor Jones's largest addition to Xenon Pharmaceuticals Inc. (XENE) was in Q1 2026, adding 495,591 shares worth $28.82 M.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 495,591 shares of Xenon Pharmaceuticals Inc. (XENE), valued at approximately $28.82 M.
As of the Q1 2026 filing, Xenon Pharmaceuticals Inc. (XENE) represents approximately 0.05% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Xenon Pharmaceuticals Inc. (XENE) was 495,591 shares, as reported at the end of Q1 2026.